48. Advances in Immunotherapy for Transplant Oncology
49. Clinical Features Of Patients Who Should Be Treated With Adjuvant Chemotherapy After Radiofrequency Therapy For Hepatocellular Carcinoma
54. Development of a Simple Predictive Method without Liver Stiffness for Significant Varices in Patients with Hepatocellular Carcinoma
55. Diagnosis of HBV-associated liver cirrhosis and hepatocellular carcinoma by mass spectrometrybased high-throughput integrative serum lipidomics and peptiomics: A retrospective study
56. Donafenib Combined with Anti-PD-1 Antibody as Adjuvant Therapy for Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Resection
57. Efficacy of Postoperative Adjuvant Therapies in Patients with resected cholangiocarcinoma
58. Evaluation of Patient-reported Outcomes (PROs) <65 or ≥65 Years Old (yo) from the CARES-310 Trial
59. Examination of cases undergoing New FP therapy after resistance to Durvalumab+Tremelimumab therapy
60. Exposure-adjusted Incidence Rates of Adverse Events in the Phase 3 CARES 310 Trial of Camrelizumab plus Rivoceranib Compared to Sorafenib
61. Gemcitabine-Based Therapy Versus Non-Gemcitabine-Based Therapy as Neoadjuvant for Liver Transplant Recipients with Cholangiocarcinoma: An Institution Experience
62. Hepatic Angiosarcoma Manifesting as Severe Thrombocytopenia
63. Impact of Baseline Liver Function on Survival Outcomes in the CARES-310 Trial
64. Impact of Cynomorium syngaricum-4 talkh on Apoptosis in Ethanol-Induced Liver Inflammation
65. Impact of viral etiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
67. LEN-TACE for unresectable intermediate stage HCC: Association Between Survival and Duration of Complete Response in TACTICS-L
68. Lenvatinib Versus Sorafenib as Second-Line Therapy Following Atezolizumab-Bevacizumab (Atezo-Bev) Failure in Unresectable Hepatocellular Carcinoma (uHCC): A Multicenter Retrospective Study from Korea and Japan
69. No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab + Bevacizumab: ARISE Study
70. Outcomes by occurrence of immune-mediated adverse events with tremelimumab plus durvalumab in the HIMALAYA study in unresectable hepatocellular carcinoma
71. Outcomes in the Asian subgroup of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
72. PHF10 Splicing Isoform P/S Regulates Hepatocellular Carcinoma Progression through Mevalonate Pathway
74. Prognostic Factors for Survival Outcomes in Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization (TACE) and Treated with Hepatic Arterial Infusion Chemotherapy (HAIC)
75. Second-line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma (uHCC) After Progression on Atezolizumab Plus Bevacizumab (Atezo-Bev): Final Results from the Phase 2 REGONEXT Trial
76. Second-line systematic strategy options for the progression of Lenvatinib plus Tislelizumab treating unresectable hepatocellular carcinoma: a retrospective study
77. Synergistic targeting of ECM stiffness: integration of matrix softening and blocking of mechanical signal transduction in primary liver cancers
80. The role of pgRNA in recurrence of advanced HCC after systematic therapy
81. The Safety of Immunotherapy in hematologic and solid organ transplant recipients: A retrospective analysis
83. Tumor burden incorporating AFP improves survival prediction for patients with HCC undergoing TACE: An international multicentre observational study
84. Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma
85. New anti-cancer targets for Tregs specific to integrin signaling
88. Cadonilimab in Combination with Tyrosine Kinase Inhibitors as Second-line or Subsequent Treatment in Hepatocellular Carcinoma (HCC): A Retrospective Real-World Study
89. Comparison of Atezolizumab Plus Bevacizumab Versus Multi-kinase Inhibitors in Patients With Transarterial Chemoembolization-refractory Unresectable HCC
90. Donafenib Combined with Anti-PD-1 Antibody and Interventional Surgery as First-line Treatment for UnresectableHepatocellular Carcinoma: A Retrospective Study
91. Durvalumab for anti-PD-1 refractory hepatocellular carcinoma
92. Factors determining durable response in hepatocellular carcinoma treatment with atezolizumab and bevacizumab
93. Infiltrative morphology is associated with the immunosuppressive tumor microenvironment and poor clinical outcomes after atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
94. Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from a phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)
96. Retreatment of Immune Checkpoint Inhibitors after Remission of Immune-related Adverse Events in Patients with Hepatocellular Carcinoma
97. The Efficacy and Safety of Atezolizumab and Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma